Skip to main content
Clinical Trials/NCT03149783
NCT03149783
Unknown
Phase 2

A Randomized Controlled Trial to Determine if Pre- and Post- Operative Regional Pain Control (Transversus Abdominis Plane Block) With Ropivacaine Versus Placebo Leads to Lower Anesthetic and Narcotic Dosing, and Alters Pain Scores

University of Colorado, Denver1 site in 1 country80 target enrollmentFebruary 13, 2018

Overview

Phase
Phase 2
Intervention
Ropivacaine HCL
Conditions
Pain, Postoperative
Sponsor
University of Colorado, Denver
Enrollment
80
Locations
1
Primary Endpoint
Pain Scores
Last Updated
4 years ago

Overview

Brief Summary

A randomized controlled trial to determine if pre- and post- operative regional pain control (transversus abdominis plane block) with ropivacaine versus placebo leads to lower anesthetic and narcotic dosing, and alters pain scores.

This study plans to learn more about regional anesthesia and pain control during abdominal surgery. The study will gather data about the effectiveness of continuous catheter infusion of local anesthetic after an abdominal operation. Outcomes include pain scores, IV pain medicine requirements, and delirium.

Registry
clinicaltrials.gov
Start Date
February 13, 2018
End Date
October 31, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \>=50 years.
  • Subjects will be undergoing an elective intra-abdominal or abdominal wall operation, including pelvic operations. Surgery specialties included are general surgery, surgical oncology, urology, gynecology, plastic surgery.

Exclusion Criteria

  • Subjects with a history of dementia or aphasia, as visual analog scale and confusion assessment will be unreliable.
  • Patients with an epidural or spinal catheter block.
  • Patients who do not speak English so that a language barrier is not confused with VAS scoring or confusion.
  • Patients who are abusing alcohol defined by a high AUDIT score (\>8) will be excluded.
  • History of bipolar disorder or a psychotic disorder (such as a psychotic major depression, schizophrenia, schizoaffective disorder, or psychosis in Alzheimer's disease or other dementia).
  • Patients with a documented allergy to ropivacaine or other sodium channel blockers.

Arms & Interventions

Ropivacaine

Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.

Intervention: Ropivacaine HCL

Placebo

Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.

Intervention: sodium chloride

Outcomes

Primary Outcomes

Pain Scores

Time Frame: Days 0-7 following the operation

Pain scores from the visual analog scale

Secondary Outcomes

  • Amount of anesthetic(During the operation)
  • Amount of narcotic administered postoperatively(Days 0-7 postop)

Study Sites (1)

Loading locations...

Similar Trials